249 related articles for article (PubMed ID: 25184175)
21. Edoxaban: a review in nonvalvular atrial fibrillation.
McCormack PL
Am J Cardiovasc Drugs; 2015 Oct; 15(5):351-61. PubMed ID: 26369340
[TBL] [Abstract][Full Text] [Related]
22. Edoxaban in atrial fibrillation patients with established coronary artery disease: Insights from ENGAGE AF-TIMI 48.
Zelniker TA; Ruff CT; Wiviott SD; Blanc JJ; Cappato R; Nordio F; Mercuri MF; Lanz H; Antman EM; Braunwald E; Giugliano RP
Eur Heart J Acute Cardiovasc Care; 2019 Mar; 8(2):176-185. PubMed ID: 30039978
[TBL] [Abstract][Full Text] [Related]
23. Edoxaban: a new oral direct factor xa inhibitor.
Camm AJ; Bounameaux H
Drugs; 2011 Aug; 71(12):1503-26. PubMed ID: 21861537
[TBL] [Abstract][Full Text] [Related]
24. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Minguet J; Sims HM; Smith KH; Bramlage P
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
[TBL] [Abstract][Full Text] [Related]
25. [New oral anticoagulants - sunset for warfarin in therapy of atrial fibrillation].
Koziński M; Obońska K; Kubica A; Navarese EP; Kubica J
Kardiol Pol; 2012; 70(10):1053-60. PubMed ID: 23080100
[No Abstract] [Full Text] [Related]
26. Spontaneous conversion in patients with non-valvular atrial fibrillation planned for electrical cardioversion: A subanalysis of the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion Of Atrial Fibrillation (ENSURE-AF) trial.
Cohen AA; Heidbuchel H; Le Heuzey JY; De Caterina R; Merino JL; Jin J; Melino M; Winters SM; Goette A; Lip GYH
Am Heart J; 2019 Mar; 209():131-135. PubMed ID: 30635112
[No Abstract] [Full Text] [Related]
27. New oral anticoagulants: their role in stroke prevention in high-risk patients with atrial fibrillation.
Ferns SJ; Naccarelli GV
Med Clin North Am; 2015 Jul; 99(4):759-80. PubMed ID: 26042881
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Aspromonte N; Colivicchi F
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
[TBL] [Abstract][Full Text] [Related]
29. Which oral anticoagulant for atrial fibrillation.
Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
[No Abstract] [Full Text] [Related]
30. Dabigatran: safer, more effective and easier to use than warfarin.
Cardiovasc J Afr; 2009; 20(5):311-2. PubMed ID: 19907807
[No Abstract] [Full Text] [Related]
31. [Edoxaban in patients with atrial fibrillation and cancer].
Maurea N; Riva L
G Ital Cardiol (Rome); 2018 Sep; 19(9 Suppl 1):13S-19S. PubMed ID: 30284558
[TBL] [Abstract][Full Text] [Related]
32. The relationship of renal function to outcome: A post hoc analysis from the EdoxabaN versus warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
Lip GYH; Al-Saady N; Ezekowitz MD; Banach M; Goette A
Am Heart J; 2017 Nov; 193():16-22. PubMed ID: 29129251
[TBL] [Abstract][Full Text] [Related]
33. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
34. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens.
Providência R; Grove EL; Husted S; Barra S; Boveda S; Morais J
Thromb Res; 2014 Dec; 134(6):1253-64. PubMed ID: 25457584
[TBL] [Abstract][Full Text] [Related]
35. Establishing Edoxaban's Role in Anticoagulation.
Guirguis E; Brown D; Grace Y; Patel D; Henningfield S
J Pharm Pract; 2016 Jun; 29(3):228-38. PubMed ID: 27169733
[TBL] [Abstract][Full Text] [Related]
36. Transition of patients from blinded study drug to open-label anticoagulation: the ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Mercuri M; Curt V; Betcher J; Grip L; Cange AL; Crompton AE; Murphy SA; Deenadayalu N; Antman EM
J Am Coll Cardiol; 2014 Aug; 64(6):576-84. PubMed ID: 25104527
[TBL] [Abstract][Full Text] [Related]
37. Quality of anticoagulation control in atrial fibrillation.
Lane DA; Lip GY
Lancet; 2010 Sep; 376(9745):935-7. PubMed ID: 20801499
[No Abstract] [Full Text] [Related]
38. Modelling projections for the uptake of edoxaban in an European population to 2050: effects on stroke, thromboembolism, and health economics perspectives.
Blann AD; Boriani G; Lip GY
Europace; 2016 Oct; 18(10):1507-1513. PubMed ID: 27876695
[TBL] [Abstract][Full Text] [Related]
39. Oral factor Xa inhibitors for the prevention of stroke in atrial fibrillation.
Piccini JP; Lopes RD; Mahaffey KW
Curr Opin Cardiol; 2010 Jul; 25(4):312-20. PubMed ID: 20520539
[TBL] [Abstract][Full Text] [Related]
40. Anticoagulation therapy. Optimal dosages and genotypes for edoxaban therapy.
Huynh K
Nat Rev Cardiol; 2015 May; 12(5):256. PubMed ID: 25824520
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
